To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
12
Once daily in both eyes (OU) in the evening (PM) for 7 days
Once daily in both eyes (OU) in the evening (PM) for 7 days
Nancy Ramirez
Bedminster, New Jersey, United States
Change in Intraocular Pressure (IOP) Over Nocturnal Time Period
The primary efficacy endpoint was the mean change from baseline in mean nocturnal IOP (defined as the mean of the 4 nocturnal time points: 21:00, 00:00, 03:00, and 06:00 hours) on Day 8/Day 9
Time frame: Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame: 7 days (day 1/2 to day 8/9)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.